New hope for rare skin cancer? drug cocktail targets resistant DFSP
NCT ID NCT07646080
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will test whether combining two newer drugs (toripalimab and anlotinib) with standard chemotherapy can shrink tumors in people with a rare skin cancer called dermatofibrosarcoma protuberans (DFSP) that has stopped responding to the usual treatment. The study plans to enroll 20 adults with advanced DFSP that cannot be surgically removed. Participants will receive the drug combination in 3-week cycles until their disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab and anlotinib combined with standard chemotherapy
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced DFSP that no longer responds to standard therapy.
- What could go wrong
- This is a small, early-phase trial with only 20 participants. The combination may cause significant side effects and may not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOFIBROSARCOMA PROTUBERANS (DFSP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.